NME1 and breast carcinoma: NME1 (previously termed NM23-H1, or nucleoside diphosphate kinase-A/NDPK-A) is an MSG prototype, exhibiting reduced expression and metastasis suppressor function in melanoma, breast carcinoma, and other human cancers [2].